Back to catalogue
№ 408 8 filings · 2026-04-16 → 2026-09-17

THE BEAUTY TECH GROUP PLC

TBTG
Personal Care, Drug and Grocery Stores Share price 479p Market cap £507m Overall fit 300 /1000

High-quality, cash-generative premium growth business at a fair but not cheap multiple — however it has essentially zero AI-receiver exposure and only moderate operating leverage, so it scores as a partial fit for an AI-receivers + operating-leverage strategy.

Fair value range 400p–540p Mid case · £520m
Absolute upside +2.5% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Three post-IPO guidance upgrades with consistent beats
  • Clean disclosure and multiple triangulating valuation methods
  • Debt-free balance sheet with high ROCE anchors downside
Limits the call
  • Short public track record (first interim as listed co)
  • Category durability of at-home beauty devices is unproven over a full cycle
Methodology

Forward P/E on FY26 adjusted EPS, cross-checked with EV/EBITDA

In one line · bull case

Only major operator covering all four at-home beauty-device technologies, compounding at 40%+ with expanding margins, 65% ROCE and net cash, available at a reasonable (not cheap) ~16x FY26 adjusted EPS.

In one line · biggest risk

At-home beauty-device demand is a relatively young category heavily concentrated in CurrentBody Skin (89% of revenue), and category fade or fashion risk would hit the growth and multiple together.

Drivers
AI beneficiary 8 /100
Consumer beauty-devices DTC; no AI-receiver angle, no proprietary data business, no AI-driven revenue line disclosed.
Operating leverage 50 /100
Marketing scales with sales (~16% of DTC) but R&D, central overhead and new lab are fixed; incremental EBITDA margin ~40%+ in recent periods but not a pure fixed-cost platform.
Earnings vs expectations 85 /100
Three upgrades since Oct 2025 IPO (FY25 beat, FY26 raised in July, FY26 EBITDA raised again in Sept) with no misses.
Growth momentum 90 /100
Revenue +44% in H1 2026, every region +25%+, Rest of World +136%; growth is accelerating not decelerating.
Moat 55 /100
Clinical validation, patents, dominant branded-search traffic (~85%) and only operator covering all four core technologies — real but not dominant.
Earnings quality 72 /100
Clean cash-converting earnings but ~£5m p.a. SBP, acquired-brand amortisation and inventory provisions warrant monitoring.
Management quality 75 /100
Founder-led (16 years), disciplined capital allocation framework, buyback alongside growth investment, candid disclosure.
Cyclicality 35 /100
Discretionary consumer purchase at premium price points, but category still growing 13–14% through recent macro softness.
Leverage 5 /100
£52m net cash, zero debt, undrawn £12.5m facility — fortress balance sheet.

The Beauty Tech Group PLC (TBTG) — Investment Research Note

Executive summary

TBTG develops, manufactures and sells premium at-home beauty devices (LED masks, microcurrent, laser) under three brands — CurrentBody Skin (89% of revenue), ZIIP Beauty, Tria Laser — predominantly direct-to-consumer across 90+ countries. Trajectory is unusually strong: revenue grew 39% in FY2025 to £141.0m and 44% in H1 FY2026 to £79.7m, with Adj EBITDA margin stepping up 400bps to 26.6% in FY2025 and a further 150bps to 26.7% in H1 2026, while the balance sheet moved from £27m net debt to £52m net cash. The single most important valuation question is whether current pricing (16–17x FY26 adjusted EPS, ~8x EV/EBITDA) adequately captures growth that is still clearly accelerating — our read is that the shares are close to fair value, with the main risk being category/fad-related rather than financial.

Fair value estimate

Methodology: forward-earnings multiple triangulated with EV/EBITDA, anchored on company guidance for FY2026 (revenue ≥£170m, Adj EBITDA ≥£48.5m 2026-09 interims).

Build:

  • FY26 Adj EBITDA £48.5m → Adj operating profit ~£40m (D&A ~£5m, SBP ~£3.5m) → Adj PBT ~£38m → ~£28m PAT at ~25% tax → ~26p adjusted EPS on 110.7m shares.
  • Base multiple range 15–22x adjusted EPS for a 25–40% top-line grower with 65% operating ROCE, net cash, and ~70% underlying FCF conversion.

Fair value range: 400p – 540p per share → implied market cap £443m – £598m. Mid ~470p → market cap ~£521m. Current market cap: £457.5m (price 432p). Absolute upside to mid: ~9%.

Cross-check: EV at 432p is ~£406m, i.e. ~8.4x FY26 Adj EBITDA — reasonable but not cheap for a specialist beauty hardware group with real category risk.

Sector context

Classification confirmed — Personal Care, Drug and Grocery Stores. Quality profile is above typical sector peers: 64% gross margin, 26% EBITDA margin, 65% operating ROCE, net cash and 40%+ growth are top-decile for consumer staples. Closest listed comparables are Oddity Tech (ODD) — DTC beauty-tech, similar economics but at a higher multiple; Olaplex (OLPX) — premium prestige beauty but post-cycle decelerating; L'Oreal (OR.PA) and Estée Lauder (EL) as valuation reference points for premium beauty generally. TBTG screens better than most on growth and ROCE, but has far less diversification and brand depth than the mega-caps.

Investment thesis

  • Category tailwind with early penetration: AHBD category grew 13–14% CAGR 2019–24, 2–4x the broader beauty market, and represents only ~1% of beauty spend in core markets 2026-04 FY2025 results. TBTG is the only major operator covering all four core technologies — a durable positioning advantage.
  • Operating-leverage flywheel is visible and strengthening: Gross margin at a half-year record 64.4%, with ZIIP ex-provision margin up ~15pp to 71.1% as acquired-brand supply chain work pays off; marketing spend ratio in the core D2C channel actually fell to 15.6% 2026-09 interims. Combined with ~85% branded search traffic, each incremental revenue £ carries meaningful incremental margin.
  • Fortress balance sheet with capital returns beginning: Zero debt, £52m net cash, 65% operating ROCE, and a newly announced up-to-£20m buyback alongside continued organic reinvestment 2026-09 interims. Three guidance upgrades since the October 2025 IPO and consistent beats on revenue and margin indicate conservative management posture.

Key risks

  • Category durability / fashion risk: At-home LED, microcurrent and RF devices sit at the intersection of beauty, tech-gadget and clinical categories, all of which have historical examples of fast peaks and faster declines. The Group leans heavily on CurrentBody Skin (89% of revenue) and on continued category awareness translating into recurring purchase 2026-04 FY2025 results — not disclosed but inferred.
  • Supply chain / tariff exposure: Manufacturing is spread across China, US, India and Thailand but US tariffs on 2025 shipments materially impacted margin before the Supreme Court judgment; a £2.2m refund flattered H1 2026 comparatives and future tariff direction is uncertain 2026-09 interims.
  • Pre-IPO shareholder overhang: An 8.8m-share secondary placing at 300p was executed on 7 May 2026 just before the IPO lock-up expired, and a six-month orderly-market arrangement for remaining pre-IPO holders runs beyond 25 November 2026 2026-05 secondary placing. More selling pressure is possible as those lock-ups wind down.

Operating leverage

TBTG openly describes its "cost base [as] predominantly variable, with limited capital investment required to support growth" 2026-09 interims — which is partly accurate (marketing scales with sales) but understates the fixed-cost structure. R&D, central overhead, warehousing, clinical studies, and the new UK laboratory investment are fixed; share-based payment (~£5m p.a.) is quasi-fixed; and plc listed-company costs are entirely fixed. The 2024→2026 scale-up shows real operating leverage: revenue roughly doubled from a ~£100m run-rate to a ~£170m guide while Adj EBITDA margin expanded from 22.6% to a guided ~28.5% at the midpoint — i.e. ~£25m of incremental revenue dropping ~£11m to EBITDA, or ~44% incremental margin. On that basis, a 10–20% revenue beat vs. the ~£170m guide would plausibly add £7–15m of operating profit (18–38% of base). That is meaningful but not the "multiple of profit" dynamic the strategy prioritises — this is a well-run premium DTC brand, not a platform with a step-function fixed-cost base.

Value-trap signals

None identified. Growth is accelerating, debt is zero, cash conversion is strong, auditor report is unqualified, and governance appears orderly (board additions, buyback authorisation, capital reduction confirmed by court). The main caveat is category durability, which is a structural question rather than a value-trap signal.

Earnings vs. expectations

Since IPO (Oct 2025), management has delivered three upgrades: FY2025 printed revenue £141m vs. a lower prospectus trajectory; FY2026 guidance was raised on 7 July 2026 from consensus £161.7m revenue/£41.5m EBITDA to ≥£170m/≥£45m; and the September interims raised FY26 EBITDA guidance again to ≥£48.5m. H1 2026 Adj EBITDA £21.3m was described as "ahead of the Board's original expectations across all key metrics". The pattern is consistent beats with sequential upward revisions — a classic newly-listed, under-promising-and-over-delivering trajectory.

Conviction

4 — high. Anchors: (i) three guidance upgrades since IPO give a well-calibrated view of near-term trajectory; (ii) disclosure quality is above average for a recent listing, with granular bridges on margin and FCF conversion; (iii) multiple valuation approaches (EV/EBITDA, P/E, growth-adjusted) land within a narrow range. Limiters: short public track record (first interim as a listed company), and genuine uncertainty about the long-term shape of the AHBD category — fair value depends materially on whether 25–40% growth persists for 2–3 more years.

Filings consulted · 8

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-17Interim Results2026-09-17_9776233_interim-results.md0.90
  2. 2026-08-24Notice OF Interim Results2026-08-24_9735282_notice-of-interim-results.md0.90
  3. 2026-07-07Upgrade TO FY Expectations And H1 Trading Update2026-07-07_9654879_upgrade-to-fy-expectations-and-h1-trading-update.md0.85
  4. 2026-06-19Result OF Agm2026-06-19_9628435_result-of-agm.md0.30
  5. 2026-05-07Result OF Secondary Placing IN Tbtg2026-05-07_9555894_result-of-secondary-placing-in-tbtg.md0.70
  6. 2026-05-06Proposed Secondary Placing IN Tbtg2026-05-06_9555581_proposed-secondary-placing-in-tbtg.md0.70
  7. 2026-04-272025 Annual Report And Accounts2026-04-27_9540117_2025-annual-report-and-accounts.md0.95
  8. 2026-04-16Final Results For The Year Ended 31 December 20252026-04-16_9522502_final-results-for-the-year-ended-31-december-2025.md1.00

This research note was authored by a large language model after reading 8 regulatory filings published between 2026-04-16 and 2026-09-17. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.